Group 1 - CG Oncology, Inc. reported a quarterly loss of $0.45 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.39, and compared to a loss of $0.36 per share a year ago, indicating an earnings surprise of -15.38% [1] - The company posted revenues of $0.05 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 90.19%, and this was a decline from revenues of $0.53 million in the same quarter last year [2] - CG Oncology, Inc. shares have lost approximately 12.3% since the beginning of the year, while the S&P 500 has only declined by -0.6% [3] Group 2 - The earnings outlook for CG Oncology, Inc. is uncertain, and future stock performance will depend on management's commentary during the earnings call [4] - The current consensus EPS estimate for the upcoming quarter is -$0.53 on revenues of $0.53 million, and for the current fiscal year, it is -$1.81 on revenues of $8.24 million [7] - The Medical - Biomedical and Genetics industry, to which CG Oncology belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates